A Study of Gaboxadol in Primary Insomnia

Lundbeck

Status and phase: Completed; Phase 3

Conditions: Primary Insomnia

Treatments: Drug: Gaboxadol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00209924

10403 (Registry Identifier)

Details and patient eligibility

About

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.

Full description

To compare hypnotic efficacy of gaboxadol with placebo in elderly outpatients with primary insomnia

Sex: All

Ages: 66+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• patients with a diagnosis of primary insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind